| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.0054 | 0.9 |